Cargando…

Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel

Aim: We reviewed the radiographic response of three patients with metastatic castration-resistant prostate cancer treated with CRXL301, a docetaxel nanoparticle. For these three patients, we isolated and analyzed circulating tumor cells (CTCs) to explore microtubule (MT) drug-target engagement (MT-D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukhtar, Eiman, Worroll, Daniel, Galletti, Giuseppe, Schuster, Shelly, Piha-Paul, Sarina A., Giannakakou, Paraskevi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556717/ https://www.ncbi.nlm.nih.gov/pubmed/33062959 http://dx.doi.org/10.20517/cdr.2019.116

Ejemplares similares

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
por: Kim, Seaho, et al.
Publicado: (2022)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2020)

Docetaxel: an alternative taxane in ovarian cancer
por: Katsumata, N
Publicado: (2003)

Structural insight into the stabilization of microtubules by taxanes
por: Prota, Andrea E, et al.
Publicado: (2023)

Microtubule disruption targets HIF-1α mRNA to cytoplasmic P-bodies for translational repression
por: Carbonaro, Marisa, et al.
Publicado: (2011)

Beyond taxanes: the next generation of microtubule-targeting agents
por: Cortes, Javier, et al.
Publicado: (2011)

Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy
por: González, Myriam, et al.
Publicado: (2021)

Glutathione S-transferases (GSTs) polymorphism and taxane (docetaxel) sensitivity in breast cancer
por: Lee, Anbok
Publicado: (2019)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
por: Bumbaca, Brandon, et al.
Publicado: (2018)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
por: Jiménez, Natalia, et al.
Publicado: (2020)

Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells
por: St. George, Marc, et al.
Publicado: (2015)

Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves
por: Marano, Francesca, et al.
Publicado: (2016)

Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer
por: Sarwar, Sadia, et al.
Publicado: (2022)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models
por: Yee, Samantha S., et al.
Publicado: (2021)

CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance
por: Langebäck, Anette, et al.
Publicado: (2019)

Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage
por: Gjyrezi, Ada, et al.
Publicado: (2021)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells
por: Hillowe, Andrew, et al.
Publicado: (2023)

Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site
por: Lo, Yu-Chen, et al.
Publicado: (2019)

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
por: Abidi, Afroz
Publicado: (2013)

Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer
por: Aksoy, Asude, et al.
Publicado: (2017)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells
por: Wang, Harris, et al.
Publicado: (2014)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes
por: Morley, Samantha, et al.
Publicado: (2015)

EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity
por: Colbert, Paul L., et al.
Publicado: (2014)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2013)

Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells
por: Eskra, Jillian N., et al.
Publicado: (2019)

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2021)

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2018)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mb5v275udmpmj3m4bg8bn6nop6